Two large cardiovascular outcome trials of canagliflozin, comprising the CANVAS Program, will complete in early 2017: the CANagliflozin cardioVascular Assessment Study (CANVAS) and the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R). Accruing data for the sodium glucose co-transporter 2 (SGLT2) inhibitor class has identified questions and opportunities that were not apparent when the trials were designed. Accordingly, a series of modifications have been made to the planned analyses. These updates will ensure that the data from the CANVAS Program will maximize advances in scientific knowledge and patient care. The specification of the analysis strategy prior to knowledge of the trial results, their design by the independent scientific trial Steering Committee, the detailed a priori definition of the analysis plans, and the external review provided by the US Food and Drug Administration all provide maximally efficient and robust utilization of the data. The CANVAS Program should significantly advance our understanding of the effects of canagliflozin, and the broader SGLT2 inhibitor class, on a range of important efficacy and safety outcomes.
| INTRODUCTION
Canagliflozin, an orally active inhibitor of sodium glucose cotransporter 2 (SGLT2), was approved for marketing in the USA on March 29, 2013 and is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM). 1 will determine the effects of canagliflozin on chronic kidney disease, but is not scheduled to complete until 2020. 4 As new data have accrued for the SGLT2 inhibitor class, it has become apparent that updating the objectives and analysis plans for the CANVAS Program prior to study completion offers opportunities to enhance the scientific, clinical and regulatory outcomes from the studies. 5 Accordingly, the present paper describes the initial study plan and analysis strategy, the rationale for modifications and the updates that have been made for CANVAS, CANVAS-R and integrated analyses of the CANVAS Program.
| DRUG DEVELOPMENT ENVIRONMENT FOR DIABETES
Historically, new therapies for diabetes were marketed on the basis of well-tolerated improvements in blood glucose control. The supporting phase III programmes typically comprised a few thousand patientyears of follow-up, with post-marketing surveillance implemented to protect against medium-to long-term risks. This model has been deemed inadequate after the high-profile withdrawal from the market of several therapies, years after marketing was first authorized, because of likely serious adverse effects on cardiovascular outcomes. 6 In December 2008, the US Food and Drug Administration (FDA) issued new guidance describing an enhanced strategy for ensuring the cardiovascular safety of drugs marketed for the management of diabetes by specifying explicit safety requirements for initial marketing authorization, as well as more robust criteria for ensuring mediumterm safety. 7 Specifically, the FDA has required evidence that the upper bound of the 95% confidence interval (CI) for the hazard ratio To meet this requirement and after discussions with the FDA, a study with directly comparable population, procedures and assessments, the CANVAS-R study, 3 was commenced in conjunction with the ongoing CANVAS trial, such that an adequately powered analysis of the data from the integrated CANVAS Program could be completed within the specified timeframe.
| CANVAS PROGRAM
The CANVAS Program comprises 2 trials, CANVAS and CANVAS-R, and includes a prespecified integrated analysis of the 2. The integrated analysis will enable the sponsor to meet the FDA postmarketing requirement to determine the cardiovascular safety of canagliflozin, as well as provide an opportunity to evaluate the potential for cardiovascular protection.
| CANVAS
The CANVAS study 2 
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(N = 10 142; integrated analysis) FIGURE 1 Overview of canagliflozin trial timelines.
* Planned; recruitment ongoing. † Note that the patient populations in CANVAS and CANVAS-R are nearly identical to facilitate an integrated analysis of the data cardiovascular disease in patients with inadequately controlled T2DM and increased cardiovascular risk. As previously described, 2 the study was initially planned with 2 stages of study enrolment. The goal of the first stage would be to substantiate the potential for cardiovascular protection by defining effects on key biomarkers and provide the initial cardiovascular safety data required for marketing approval.
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The second stage would then expand recruitment with the aim of demonstrating protection against serious cardiovascular events. 
| CANVAS-R
The CANVAS-R study 3 is a second large prospective, randomized, double-blind, placebo-controlled clinical trial of patients with T2DM
with a history or a high risk of cardiovascular events. CANVAS-R was initiated after marketing authorization in the USA and in response to the FDA regulatory requirement for a "CANVAS-like" study, the data from which could be combined with data from the ongoing CANVAS trial to address the specified post-marketing safety requirements.
Participants in CANVAS-R have nearly identical inclusion criteria to those of CANVAS and have been assigned to once-daily placebo or canagliflozin 100 mg (with optional uptitration to 300 mg) for a planned average of 2 years of follow-up. The dosing strategy was selected to reflect the labelling instructions in many countries in which canagliflozin is approved. The separate primary objective of CANVAS-R is attenuation of kidney disease progression, as evidenced by fewer transitions from normo-to micro-or macro-, or micro-to macroalbuminuria. The secondary objectives defined in the original protocol were to determine corresponding effects on the regression of albuminuria, on estimated glomerular filtration rate and on albumin:creatinine ratio. To enable the study to meet the postmarketing evaluation of cardiovascular safety in the integrated analysis of data across the CANVAS Program, the procedures for recording and managing serious adverse events and endpoint adjudication across the 2 trials are identical (Table 1) , as are the participant characteristics (Table 2 ). This includes the use of a common independent and blinded Endpoint Adjudication Committee that operates to the same Charter that is used for CANVAS. CANVAS-R completed randomization of 5812 individuals between January 2014 and May 2015 and median follow-up is currently 1.7 years.
The characteristics of patients enrolled in the CANVAS Program are summarized in Table 2 . A total of 10 142 participants were randomized to the studies, including 65% with a history of cardiovascular disease and 35% with at least 2 risk factors for cardiovascular disease. The characteristics of the patients enrolled in CANVAS and CANVAS-R were similar with respect to duration of T2DM, microvascular disease and atherosclerotic cardiovascular disease. 
| Accumulating evidence about the effects of SGLT2 inhibition
Since the design of CANVAS and CANVAS-R, substantial new data have been reported about the effects of SGLT2 inhibitors on clinical outcomes. This includes evidence about possible new risks, such as diabetic ketoacidosis, 11 bone fracture 12, 13 and amputation, 14, 15 as well as a possible protective effect for some cardiovascular and renal outcomes. In particular, the 2015 report of the EMPA-REG OUT-COME trial implied large benefits for cardiovascular death, heart failure, total mortality and kidney outcomes. 16, 17 A recent meta-analysis of the totality of the evidence describing the effects of SGLT2 inhibition indicates that the EMPA-REG OUTCOME findings are consistent with the broader evidence base and that the EMPA-REG OUTCOME results are likely to provide a good approximation of the effects of other agents in this class 5 ; however, many of the analyses were post hoc, the numbers of events included in some were small and there is an urgent need to determine their repeatability in adequately powered, prespecified analyses of large new datasets with adjudicated data. The soon-to-be-completed CANVAS Program provides a unique near-term opportunity to achieve this, but modification of the existing objectives will be required to enable the a priori specification of the most important outstanding questions and the robust testing of key hypotheses in the CANVAS Program.
| PRINCIPLES UNDERPINNING THE UPDATED ANALYSIS STRATEGY
The accumulating data about SGLT2 inhibitors provides much better insight into the most likely effects of canagliflozin than was available size, the CANVAS Program will have reasonable power to test efficacy for several outcomes. Specifically, the apparently large effects of SGLT2 inhibition on vascular death, total mortality, heart failure and kidney disease present opportunities to test hypotheses of protection related to these outcomes that were not previously considered feasible with the quantity of data accrued within CANVAS, CANVAS-R or even across the integrated data from the 2 trials.
| Minimization of the risk of chance findings
The minimization of the risk of chance findings is being achieved through the use of a sequential testing process, which was also a feature of the original protocols for both CANVAS and CANVAS-R;
however, because the updated analysis plan will include testing of both safety and efficacy in the individual and the integrated datasets, a new single sequential testing plan has been defined. This plan covers all the main hypotheses from the integrated and individual study datasets, and will control type I error at 5% across all.
| Outcomes for investigation
Primary, secondary and exploratory outcomes have been updated to focus on complications of diabetes for which benefits appear likely to be detectable. Accordingly, analyses of vascular death, total mortality, heart failure and kidney disease have been prioritized. In parallel, analyses of outcomes addressing myocardial infarction for which effects appear lesser or absent, and stroke for which SGLT2 inhibition may cause harm, 5 have been refined. In terms of multicomponent outcomes, the regulatory assessment of cardiovascular safety is reasonably based on MACE, a broad composite that encompasses the most common serious vascular outcomes experienced by patients with diabetes; however, if there are effects of different magnitude or direction on specific cardiovascular outcomes, the use of a composite will conceal important information about the effects of the agent. As such, in addition to the prescribed safety analyses on composite cardiovascular events, additional analyses investigating effects on causespecific outcomes are now proposed.
| Protection against the risks of bias or confounding
Protection against the risks of bias or confounding has been central to the designs of CANVAS, CANVAS-R and the planned integrated analysis of the CANVAS Program, and is achieved through randomization, blinding and intention-to-treat analysis. Premature discontinuation of treatment by some patients will result in underestimation of the true effects of the drug on most outcomes, but the likely impact can be quantified and the direction of the effect is known. Considerable efforts are being made to maximize the completeness of followup but sensitivity analyses using each of worst-case single imputation, multiple imputation and delta methods will be undertaken to identify the range of possible effects of missing data for key outcomes.
There is also a potential for bias that results from the interim unblinding of the CANVAS data, because it is possible that the implementation of the study differed after the data were revealed (operational bias), or that the decision to continue with the study itself was based on that knowledge (a statistical bias). In practice, the likelihood of important bias is small because the trial was planned to continue and did, substantive changes to the CANVAS protocol have Left-truncation of the data will result in an unbiased estimate of effect for the entire study if the proportional effect of the intervention on the outcome of interest is constant over time, as appears to be the case for fatal outcomes with SGLT2 inhibitors 16 ; however, if greater benefits accrue early in treatment rather than later, as may be the case, for example, for the effects of SGLT2 inhibitors on heart failure, then left-truncation would result in a biased estimate of the overall treatment effect. 16 The constancy of treatment effects over time, and the constancy of effects across the 2 studies, which have different durations of follow-up, will be examined.
| Achieving regulatory outcomes
The primary goal of reviewing the analysis strategy for CANVAS, CANVAS-R and the integrated CANVAS Program datasets has been to maximize the opportunity to make new scientific discoveries from the data; however, the ultimate goal is to improve the care of patients with diabetes and, importantly, the uptake of new therapies by clinicians is determined by their regulatory status. As such, throughout the review process, an additional consideration in updating the analytical approach has been to maximize concurrently the possibility of achieving appropriate new indications to be reflected in labelling.
| UPDATED HYPOTHESES AND OUTCOMES FOR INVESTIGATION
The initial and updated plans for hypothesis testing in CANVAS, CANVAS-R and the integrated CANVAS Program data are summarized in Table 3 . Table 4 shows the full set of primary, secondary and exploratory outcomes that will be evaluated. The strategy for control of the type I error at 5% for multiple hypothesis testing is shown in If the MACE and the mortality endpoints tested on the integrated dataset succeed in rejecting the null hypotheses, all of the alpha for testing (ie, 5%) will pass to the CANVAS-R dataset for testing of the renal and cardiovascular efficacy hypotheses specified for that study. No alpha is preserved for evaluating hypotheses in CANVAS and only nominal P values will be reported for all other endpoints assessed in the CANVAS, CANVAS-R and integrated CANVAS Program datasets. The truncated integrated dataset will only be used for testing the hypotheses of protection against total mortality and cardiovascular mortality, with the primary outcome and all exploratory outcomes planned for the integrated data to be investigated using the full integrated CANVAS Program dataset.
The anticipated numbers of events, assumed minimum effect sizes and projected statistical power for the hypothesis testing are shown in Table 5 . The analyses of mortality outcomes based on the left-truncated dataset will be carefully examined for evidence of varying effects of the intervention over time. If present, then the focus of reporting for these outcomes will be on the subsidiary analyses based on the full dataset.
| SAFETY ANALYSES
In the same way that analysis of the integrated data from CANVAS and CANVAS-R will provide a more precise and reliable assessment of the efficacy of the compound, so too will evaluations of the integrated data provide a better assessment of non-cardiovascular safety.
The safety analyses will be based on an on-treatment analysis set as the approach least likely to favour canagliflozin, unless otherwise a All hypotheses will test for superiority except for the cardiovascular safety hypothesis, which will test for non-inferiority. Note: initial cardiovascular safety for marketing authorization was demonstrated using the MACE plus outcome (MACE plus hospitalization for unstable angina) based on interim data from CANVAS and data from 8 other phase II and phase III trials of canagliflozin that were completed by January 2012.
b Prespecified substudies of CANVAS in subgroups of patients receiving protocol-specified dosages of (1) insulin, (2) sulphonylurea monotherapy or (3) peroxisome proliferator-activated receptor γ (PPARγ) agonist plus metformin evaluated the following at week 18: Primary: change from baseline in HbA1c; Secondary: effects on body weight, FPG-lowering efficacy, proportion of patients reaching HbA1c <7.0%, systolic and diastolic BP, fasting plasma lipids (triglycerides, HDL cholesterol, LDL cholesterol, total cholesterol and the ratio of LDL cholesterol to HDL cholesterol). The substudies were published previously. The following variables will be assessed in the substudy populations at weeks 26 and 52: effects on glycaemic efficacy (HbA1c and FPG), body weight, systolic and diastolic BP and fasting plasma lipids.
c Will be evaluated using left-truncated data from CANVAS and all data from CANVAS-R.
specified, and all instances of relevant adverse events collected across the 2 studies, regardless of whether they were collected in exactly the same way, will be included. That said, the evaluation of clinical laboratory test results and vital signs will be made only at the visits that are commonly scheduled in CANVAS and CANVAS-R. The integrated safety analyses will be based on the observed data with no imputation of missing values, and the combined doses of canagliflozin will be compared against placebo for the primary analyses.
Analyses will be of serious adverse events grouped into major categories defined by the Medical Dictionary for Regulatory Activities (MedDRA), 18 adverse events that resulted in study drug discontinua- 
| CONCLUSION
The updates to the analysis strategy for CANVAS, CANVAS-R and the CANVAS Program proposed in the present paper will ensure that 
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